News | September 12, 2025
A.forall expands US generics portfolio
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
A triple-action Formula for comprehensive respiratory relief
Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma
J B Chemicals and Pharmaceuticals receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
This approval authorizes the company to export Ibuprofen to the Chinese markets
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
_256_384.jpg)
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
Subscribe To Our Newsletter & Stay Updated
